US OptionsDetailed Quotes
HUMA241220P12500
- 6.71
- 0.000.00%
15min DelayClose Nov 27 16:00 ET
0.00High0.00Low
6.71Open6.71Pre Close0 Volume8 Open Interest12.50Strike Price0.00Turnover239.67%IV-31.59%PremiumDec 20, 2024Expiry Date8.10Intrinsic Value100Multiplier23DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9289Delta0.0574Gamma0.54Leverage Ratio-0.0068Theta-0.0042Rho-0.50Eff Leverage0.0015Vega
Humacyte Stock Discussion
Sign in to post a comment
$Humacyte (HUMA.US)$
🥱🥱🥱😴😴😴
🥱🥱🥱😴😴😴
1
1
$Humacyte (HUMA.US)$
🚀🚀🚀 USD 6 Stsge 3 results going to be announced... parking.
🚀🚀🚀 USD 6 Stsge 3 results going to be announced... parking.
2
2
NOTE: NFA. Do not open position without buy pressure, volume. Check indicators, chart.
I see more Quantum play this week.
$Quantum (QMCO.US)$ AWS launched QuantumEmbark. Up after hours. Small float. 0 shares LTB.
$Arqit Quantum (ARQQ.US)$ AWS launched Quantum Embark.Increased market cap which translates to stock increasing in stock value and increased confidence in the stock. Low floa...
I see more Quantum play this week.
$Quantum (QMCO.US)$ AWS launched QuantumEmbark. Up after hours. Small float. 0 shares LTB.
$Arqit Quantum (ARQQ.US)$ AWS launched Quantum Embark.Increased market cap which translates to stock increasing in stock value and increased confidence in the stock. Low floa...
57
8
$Humacyte (HUMA.US)$ Humacyte To Present Phase 3 Results Comparing Efficacy And Safety Of Tissue-Engineered Vessel To AV Fistulas In End-Stage Renal Disease Patients At VEITH Symposium On November 23, 2024
Benzinga· 3 mins ago
Benzinga· 3 mins ago
1
$Humacyte (HUMA.US)$
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)
Humacyte (Nasdaq: HUMA) announced it will present Phase 3 results comparing the efficacy and safety of its acellular tissue engineered vessel (ATEV™) with autologous AV fistulas in end-stage renal disease patients. The presentation will be delivered by Dr. Charles Keith Ozaki at the 51s...
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)
Humacyte (Nasdaq: HUMA) announced it will present Phase 3 results comparing the efficacy and safety of its acellular tissue engineered vessel (ATEV™) with autologous AV fistulas in end-stage renal disease patients. The presentation will be delivered by Dr. Charles Keith Ozaki at the 51s...
1
$Humacyte (HUMA.US)$ shd i sell this shit stock ?
2
$Humacyte (HUMA.US)$ Humacyte Presents Preclinical Results Of Small-Diameter ATEV For Coronary Artery Bypass Grafting At American Heart Association's Scientific Sessions 2024; SdATEV Was Observed To Recellularize With Host Cells And Remodel To Effectively Reduce The Initial Size Mismatch Between The SdATEV And The Animal's Native Artery
– sdATEVs maintained sustained patency throughout the six-month study –
– sdATEV was observed to recellularize with host cells and remodel to effectively re...
– sdATEVs maintained sustained patency throughout the six-month study –
– sdATEV was observed to recellularize with host cells and remodel to effectively re...
2
$Humacyte (HUMA.US)$
what happened? the earnings suck but now the stock is rising
what happened? the earnings suck but now the stock is rising
1
$Humacyte (HUMA.US)$ Look at the price target from two days ago..$25..
Do you think that is a credibility issue maybe they raise this company some money along the way and they need to be bullish to get potential business from them in the future.
Do you think that is a credibility issue maybe they raise this company some money along the way and they need to be bullish to get potential business from them in the future.
1
5
unbelievable , looking at success rate and returns my success rate and return is little bit higher around above breakeven current year 
No comment yet
102875548 OP : Wake up a bit, tide coming....
